Sartorius Appoints Internatio?nally Experience?d Laboratory Manager to Join its Top Management Team
Effective 1 April 2014, Michael Melingo will head marketing, sales and services of the Lab Products & Services Division at Sartorius. He will therefore succeed Dominique Baly, who will retire from the company as planned after reaching retirement age. Michael Melingo will report to CEO and Executive Board Chairman Dr Joachim Kreuzburg and be a member of the Group Executive Committee, the highest operational management level of the Sartorius Group.
Michael Melingo, who brings more than 30 years of experience in the industry as a sales and marketing executive, will be joining Sartorius from Metrohm, the Swiss manufacturer of analytical instruments, where he was CEO of its US subsidiary. Before that, he had worked for Baxter, Bio-Rad, Millipore and Waters in Europe and Asia. Michael Melingo is of Austrian nationality and a bioengineer who specializes in biochemistry and food technology.
“With Michael, we have found an exceptionally experienced manager to join our team, who has successfully managed international laboratory businesses. In his new role at Sartorius, he will focus on further developing the global sales, marketing and service organization of our laboratory division business and strengthen its strategic positioning,” said Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.